As Lilly Wades Through The Patent Cliff, It Sees Hope In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Citi Investment Research says Lilly is the “best positioned” among U.S. pharma in China; here’s why.
You may also be interested in...
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D
BEIJING - Alarmed by a 2010 study that showed China lies at the epicenter of an explosion in new diabetes cases, China's Ministry of Health is stepping up physician training courses and planning screening services across major cities, according to Chinese and Western scholars
Shiseido Unveils Strategy For Returning Company To Growth In 2013
Shiseido has strategic initiatives planned for its domestic and Chinese businesses and Bare Escentuals in the U.S. following a disappointing fiscal 2012 in which the Toyko-based firm recorded a net loss of $148 million.